Tombul İsmail, Sayan Muhammet, Mustafa Demiröz Şevki, Çelik Ali, Kurul İsmail Cüneyt, Taştepe Abdullah İrfan, Arıbaş Olgun Kadir
Department of Thoracic Surgery, Ankara Training and Research Hospital, Ankara, Türkiye.
Department of Thoracic Surgery, Gazi University Faculty of Medicine, Ankara, Türkiye.
Turk Gogus Kalp Damar Cerrahisi Derg. 2025 Jun 27;33(3):349-356. doi: 10.5606/tgkdc.dergisi.2025.26607. eCollection 2025 Jul.
This study aims to identify prognostic factors in operated patients with non-small cell lung cancer staged as T3N0M0 according to the 8 edition of the Tumor, Node, Metastasis (TNM) staging system.
Between January 2010 and June 2023, a total of 79 patients (67 males, 12 females; mean age: 62.9±8.7; range, 40 to 80 years) who underwent surgery for non-small cell lung cancer and were pathologically staged as T3N0M0 were retrospectively analyzed. The patients were divided into two groups: the first group included 56 patients with a single T3 factor, while the second group included 23 patients with multiple T3 factors. Survival analysis was performed.
The five-year overall survival rate for the first group was 79.0%, with a mean overall survival of 107.76±8.44 months (95% confidence interval [CI]: 91.21-124.32), while the second group had a five-year overall survival rate of 48.9%, with a mean overall survival of 69.19±12.60 months (95% CI: 44.48-93.91). This difference was statistically significant (p=0.02). In the multivariate analysis, multiple T3 factors (p=0.003) and the presence of comorbidity (p=0.004) were found to be independent poor prognostic factors.
Our study results suggest that having multiple T factors significantly and adversely affect survival of patients with surgically treated pT3 non-small cell lung cancer.
本研究旨在根据第八版肿瘤、淋巴结、转移（TNM）分期系统，确定接受手术治疗的T3N0M0期非小细胞肺癌患者的预后因素。
回顾性分析2010年1月至2023年6月期间，79例接受非小细胞肺癌手术且病理分期为T3N0M0的患者（67例男性，12例女性；平均年龄：62.9±8.7岁；范围40至80岁）。患者分为两组：第一组包括56例单一T3因素患者，第二组包括23例多个T3因素患者。进行生存分析。
第一组的五年总生存率为79.0%，平均总生存期为107.76±8.44个月（95%置信区间[CI]：91.21 - 124.32），而第二组的五年总生存率为48.9%，平均总生存期为69.19±12.60个月（95% CI：44.48 - 93.91）。这种差异具有统计学意义（p = 0.02）。在多因素分析中，多个T3因素（p = 0.003）和合并症的存在（p = 0.004）被发现是独立的不良预后因素。
我们的研究结果表明，多个T因素对接受手术治疗的pT3期非小细胞肺癌患者的生存有显著不利影响。
